CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business